PMID- 27806087
OWN - NLM
STAT- MEDLINE
DCOM- 20170626
LR  - 20231111
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 11
DP  - 2016
TI  - Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 
      Diabetes in China.
PG  - e0165629
LID - 10.1371/journal.pone.0165629 [doi]
LID - e0165629
AB  - OBJECTIVE: To estimate the long-term cost-effectiveness of dapagliflozin versus 
      acarbose as monotherapy in treatment-naive patients with type 2 diabetes mellitus 
      (T2DM) in China. METHODS: The Cardiff Diabetes Model, an economic model designed 
      to evaluate the cost-effectiveness of comparator therapies in diabetes was used 
      to simulate disease progression and estimate the long-term effect of treatments 
      on patients. Systematic literature reviews, hospital surveys, meta-analysis and 
      indirect treatment comparison were conducted to obtain model-required patient 
      profiles, clinical data and costs. Health insurance costs (2015 yen) were estimated 
      over 40 years from a healthcare payer perspective. Univariate and probabilistic 
      sensitivity analyses were performed. RESULTS: The model predicted that 
      dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and 
      mortality events, was associated with a mean incremental benefit of 0.25 
      quality-adjusted life-years (QALYs) and with a lower cost of  yen8,439 compared with 
      acarbose. This resulted in a cost saving of  yen33,786 per QALY gained with 
      dapagliflozin. Sensitivity analyses determined that the results are robust. 
      CONCLUSION: Dapagliflozin is dominant compared with acarbose as monotherapy for 
      Chinese T2DM patients, with a little QALY gain and lower costs. Dapagliflozin 
      offers a well-tolerated and cost-effective alternative medication for 
      treatment-naive patients in China, and may have a direct impact in reducing the 
      disease burden of T2DM.
FAU - Gu, Shuyan
AU  - Gu S
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang, China.
FAU - Mu, Yiming
AU  - Mu Y
AD  - Department of Endocrinology and Metabolism, Chinese PLA General Hospital, Chinese 
      PLA Medical College, Beijing, China.
FAU - Zhai, Suodi
AU  - Zhai S
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
FAU - Zeng, Yuhang
AU  - Zeng Y
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang, China.
FAU - Zhen, Xuemei
AU  - Zhen X
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang, China.
FAU - Dong, Hengjin
AU  - Dong H
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou City, Zhejiang, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20161102
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - T58MSI464G (Acarbose)
SB  - IM
MH  - Acarbose/administration & dosage/*economics
MH  - Benzhydryl Compounds/administration & dosage/*economics
MH  - China
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucosides/administration & dosage/*economics
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*economics
MH  - Male
MH  - Middle Aged
MH  - Models, Economic
MH  - Quality-Adjusted Life Years
MH  - Treatment Outcome
PMC - PMC5091768
COIS- This study was funded by AstraZeneca. The funders had no role in study design, 
      data collection and analysis, decision to publish, or preparation of the 
      manuscript. This does not alter our adherence to PLOS ONE policies on sharing 
      data and materials.
EDAT- 2016/11/03 06:00
MHDA- 2017/06/27 06:00
PMCR- 2016/11/02
CRDT- 2016/11/03 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2016/10/15 00:00 [accepted]
PHST- 2016/11/03 06:00 [pubmed]
PHST- 2017/06/27 06:00 [medline]
PHST- 2016/11/03 06:00 [entrez]
PHST- 2016/11/02 00:00 [pmc-release]
AID - PONE-D-16-31060 [pii]
AID - 10.1371/journal.pone.0165629 [doi]
PST - epublish
SO  - PLoS One. 2016 Nov 2;11(11):e0165629. doi: 10.1371/journal.pone.0165629. 
      eCollection 2016.